Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
96.417,35
-0,81%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Xeris Biopharma Holdings Inc (XERS) Xeris Biopharma Holdings Inc (XERS) Notizie

XERS

Xeris Biopharma (XERS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XERS
DataOraFonteTitoloSimboloCompagnia
26/11/202413:00Business WireXeris to Participate in Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202422:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202413:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202413:00Business WireXeris Biopharma Reports Third Quarter 2024 Financial ResultsNASDAQ:XERSXeris Biopharma Holdings Inc
31/10/202413:00Business WireXeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
04/10/202422:05Business WireXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
22/08/202413:00Business WireXeris to Participate in Upcoming Investor ConferencesNASDAQ:XERSXeris Biopharma Holdings Inc
09/08/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
08/08/202422:27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:XERSXeris Biopharma Holdings Inc
08/08/202413:00Business WireXeris Biopharma Reports Second Quarter 2024 Financial ResultsNASDAQ:XERSXeris Biopharma Holdings Inc
02/08/202423:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
25/07/202413:00Business WireXeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
08/07/202413:00Business WireXeris Biopharma Announces CEO Succession PlanNASDAQ:XERSXeris Biopharma Holdings Inc
03/06/202413:00Business WireXeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024NASDAQ:XERSXeris Biopharma Holdings Inc
30/05/202413:30Business WireXeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)NASDAQ:XERSXeris Biopharma Holdings Inc
30/05/202413:00Business WireXeris to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
09/05/202413:00Business WireXeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsNASDAQ:XERSXeris Biopharma Holdings Inc
06/05/202413:00Business WireXeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta BionicsNASDAQ:XERSXeris Biopharma Holdings Inc
02/05/202413:00Business WireXeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
03/04/202422:05Business WireXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
02/04/202413:00Business WireXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202422:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202413:02Business WireXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent EventsNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202413:00Business WireXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalNASDAQ:XERSXeris Biopharma Holdings Inc
28/02/202413:00Business WireXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
05/02/202413:00Business WireXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202416:12Dow Jones NewsXeris Biopharma Shares Climb 12% on Amgen License AgreementNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202414:53Dow Jones NewsXeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease TreatmentNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202414:00Business WireXeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of TeprotumumabNASDAQ:XERSXeris Biopharma Holdings Inc
04/01/202413:00Business WireXeris Biopharma Updates Its Outlook for 2023NASDAQ:XERSXeris Biopharma Holdings Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XERS

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
SPM
Saipem
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
RACE
Ferrari NV
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
TEN
Tenaris
BIT
MONC
Moncler
BIT
FBK
Finecobank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network